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Category: Review article 
 
Significance: Pain affects up to 40% of cancer survivors and affects at least 66% of patients with 
advanced progressive disease, many of whom experience poor pain control. These 10 standards are 
aimed to improve cancer pain management, promote the quality of care of patients and reduce 
variation across Europe.  
 
Abstract 
Background and Objective: Pain is a common symptom in patients that survive cancer and in those 
that live with progressive advanced disease. Evidence from meta-analyses suggests that pain 
remains poorly controlled for a large proportion of patients; barriers to good management include 
poor assessment of pain, inadequate support for patient self-management, and late or inadequate 
access to strong opioid analgesia in those with advanced disease.   
 
Methods: The European Pain Federation (EFIC) established a Task Force in 2017 which convened a 
European group of experts, drawn from a diverse range of relevant clinical disciplines, to prepare a 
position paper on appropriate standards for management of cancer-related pain. The expert panel 
reviewed the available literature and made recommendations using the GRADE system to combine 
quality of evidence with strength of recommendation. The panel took into account the desirable and 
undesirable effects of the management recommendation, including the cost and inconvenience of 
each when deciding the recommendation. 
 
Results and conclusions: The 10 standards presented are aimed to improve cancer pain management 
and reduce variation in practice across Europe. The Task Force believes that adoption of these 
standards by all 37 countries will promote the quality of care of patients with cancer related pain 
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1. Introduction 
 
Each year, approximately 3.45 million Europeans are diagnosed with cancer of whom 66% will 
survive for at least five years and 40% will be alive more than 10 years after their diagnoses [Ferlay 
et al 2013, Glare et al 2014].  
 
Pain is the commonest symptom of cancer at diagnosis [Breivik et al 2009] and rises in prevalence 
throughout and beyond cancer treatment [van den Beuken-van Everdingen et al 2016]. Between 
33% and 40% of cancer survivors (persons with cancer whose curative treatment was completed) 
suffer from chronic pain [Paice et al 2011, Seretny et al 2014, Boland and Ahmedzai 2017]. In 
contrast, 1.7 million European cancer patients die from their disease each year of whom at least 66% 
will experience pain before death and 55% will experience moderate to severe intensity pain [Ferlay 
et al 2013, van den Beuken-van Everdingen et al 2016]. 
 
It is more than 30 years since the publication of the WHO method or guidelines for cancer pain relief 
[World Health Organisation 1996]. Despite this and the publication of European guidelines [Raphael 
et al 2010a, Caraceni et al 2012, Ripamonti et al 2012, Swarm et al 2013], there remain barriers to 
good control of cancer-related pain [Oldenmenger et al 2009]. At least one third of patients are 
under-treated which is often due to inadequate attention to pain during regular oncological 
treatment, and inequitable or delayed access to opioids [Greco et al 2014, Gagnon et al 2015, Te 
Boveldt et al 2015, Ziegler et al 2016,]. Uncontrolled or undertreated pain may become physically 
and emotionally disabling, leading to increased suffering and reduced quality of life [Te Boveldt et al 
2013].  
 
A Task Force was sourced by the European Pain Federation (EFIC) in 2017. In line with other 
standards development groups, a panel of international experts was instituted, chaired by EE and 
MB. Experts from European countries were invited by email to participate, explaining the rationale 
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EFIC recognizes that improving the experience of patients with cancer-related pain requires actions 
that focus on patients, clinicians and healthcare providers or systems.  The EFIC Task Force on 
cancer-related pain reviewed existing evidence based guidelines and reached a consensus on the 
standards for the management of cancer-related pain across all 37 European countries that are 
members of the European Pain Federation (EFIC). This paper describes 10 standards that EFIC 
member countries should institute or be working towards. The standards do not specify which 
healthcare professional(s) should conduct assessments, agree management plans, provide tailored 
treatment and support, or refer for more specialized advice and treatment. The Task Force 
considered that all services involved in the care of patients with cancer should consider how best to 
meet these standards considering local expertise and resources. These standards may also prompt 
greater collaboration between clinicians in pain medicine, palliative care and oncology to meet the 
needs of patients with cancer-related pain.      
The GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) system was used to determine recommendations for each standard based on quality of 
evidence and strength of recommendation (Guyatt et al 2008). Recommendations were judged by 
the Task Force based on weighing up the desirable and undesirable effects of the management 
recommendation, including the cost and inconvenience of each. Each Task Force member was asked 
to assign a recommendation for each standard, and the final recommendation was based on 




Standard 1. Patients with a history of cancer should be routinely screened for pain at every 
engagement with a health care professional. [GRADE 1B] 
 
Supporting patients with cancer-related pain requires systematic screening for pain symptoms for 
both patients in remission and those with ongoing disease [Swarm et al 2013, Williams et al 2015, 
Trowbridge et al 1997]. Patients are often reluctant to disclose pain as they do not perceive 
healthcare professionals are interested or have the time, and these attitudes are often consolidated 
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pain can be achieved by using routine questions in consultations; for example ‘Have you experienced 
pain that interferes with daily activities?’, or by use of paper or electronic questionnaires in clinics or 
on hospital wards, such as Numerical Rating Scales (NRS) or Visual Analogue Scales (VAS).  
 
Standard 2. Patients identified with cancer-related pain should receive a pain assessment when 
seen by a healthcare professional, which at a minimum classifies the cause of pain based on 
proposed ICD-11 taxonomy and establishes the intensity and impact on quality of life of any pain 
that they report. [GRADE 1B] 
 
Cancer-related pain has multiple etiologies including the cancer itself (cancer pain) and cancer 
treatments, particularly surgery, chemotherapy (including hormonal, biological and immune 
therapies) and radiotherapy [Bennett 2017]. It can originate from visceral, bone or nerve tissues and 
can have nociceptive, neuropathic or inflammatory mechanisms [Knudsen et al 2009, Falk and 
Dickenson 2014]. It also varies in its temporal characteristics: it can be acute or chronic, and may 
have continuous or episodic features [Portenoy and Caraceni 1999]. Persistent cancer pain can lead 
in some individuals to the development of chronic widespread pain induced by plastic changes in the 
somatosensory nervous system [Kosek et al 2016]. 
 
Pain may also be caused by co-morbid conditions unrelated to cancer and this aetiology accounts for 
around 10-20% of pains in cancer patients [Bennett 2012, Grond 1996]. Therefore, pain in a cancer 
patient is not synonymous with cancer-related pain; a clinical assessment must distinguish between 
cancer pain, cancer treatment pain and pain from co-morbid conditions.   
 
Often, patients experience mixed types of pain simultaneously, or pain that changes over time. A 
detailed diagnostic assessment that must be repeated at appropriate intervals is therefore often 
required to guide treatment strategies.   
 
A bedside assessment can determine the intensity, aetiology, character and underlying mechanisms 
of pain leading to improvements in pain outcomes [Trowbridge et al 1997]. The new proposed ICD-
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practice and research and should be used widely [Treede et al 2015, Bennett et al 2018]. The Brief 
Pain Inventory provides a summary of the severity and impact of the pain on the patient’s daily 
activities [Cleeland et al 1994]. Additionally, conditions which can amplify pain expression such as 
distress, anxiety and depression [Laird et al 2016], delirium or effects of alcohol and mis-used drugs, 
should be incorporated in a structured pain assessment (Table 2).  
 
Standard 3. A multimodal pain management plan should be agreed with the patient that explains 
the causes of their pain and its likely prognosis, the need for further investigations, the 
multimodal treatment options, and includes the patient’s preferences and goals for treatment. 
[GRADE 1C] 
 
Cancer patients with pain are keen to understand the cause of their pain, what to expect, options for 
pain control, and how to cope with cancer pain including talking with others and finding help 
[Bender et al 2008]. Longitudinal interview studies reveal that pain is very dynamic and complex for 
patients and that pain control is often a trial and error process that requires continuous work 
[Hackett et al 2016]. Cognitive and other side effects of analgesia for cancer-related pain impact on 
quality of life [Sloot et al 2015]. Patients often try to manage by reducing interference from both 
pain and these side-effects to maintain as much function as possible. This ‘trading- off’ between pain 
and side effects can impact on medication adherence and should be acknowledged within the pain 
management plan [Manzano et al 2014, Flemming 2010].  
 
The goals of cancer-related pain management should therefore be to reduce the pain and its impact 
on daily living though tailored treatment, and to increase each patient’s ability for self-management 
[Gibbins et al 2014, Bennett 2017]. Helping patients to achieve this balance and identifying realistic 
expectations of treatments (for example that pain may be controlled to an acceptable degree rather 
than relieved completely) are important for improved patient outcomes. 
 
The care of many patients with cancer may be provided by different healthcare professionals 
simultaneously, for example a surgeon, oncologist, or primary care physician. It is therefore essential 
that all healthcare professionals who are involved in the care of patients with cancer-related pain be 










This article is protected by copyright. All rights reserved. 
to a competent specialist when needed (see standard 7). However, most patients can be adequately 
treated at a non-specialized care level and on an outpatient basis. Proper co-ordination is required 
between the different healthcare professionals to ensure consistent and quality care.    
 
Standard 4. Patients should receive tailored multimodal treatment which reduces the pain and its 
impact on daily living and that may include a combination of medicines, non-pharmacological 
treatments, oncological interventions, physical rehabilitation, and psychosocial or spiritual 
support. [GRADE 1A] 
 
Patients must have access to drugs and other interventions which are tailored to them. This means 
that the treatments are believed to be effective in their type of cancer-related pain, and that they 
are consistent with the patient’s preferences and goals for treatment.  
Analgesic medication that is appropriate for the patient and their pain should be available within 24 
hours of a pain assessment where indicated; this must include access to a prescriber as well as 
access to a dispensed prescription (Table 3).  
 
Prescribers should adhere to regional or national protocols or evidence based guidelines for cancer-
related pain [Raphael et al 2010b, Swarm et al 2013, Caraceni et al 2012, Ripamonti et al 2012] as 
this improves outcomes for patients [Du Pen et al 1999, Cleeland et al 2005]. 
Although analgesic medications are a cornerstone in the management of cancer-related pain, the 
use of other modalities and procedures can often improve outcomes. 
  
Access to opioid analgesia is critical for pain related to advanced and progressing cancer.  
For patients with cancer-related pain who are in the last weeks or days of life, a tailored treatment 
plan is especially important and should anticipate analgesic needs [NICE 2015]. Medications aimed 
to treat opioid related side effects such as laxatives, peripheral opioid antagonists and anti-emetics 
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Opioid analgesia may not always be suitable for long term management of pain related to cancer 
treatments (chemotherapy or surgery) in the context of disease that has been cured or is in 
remission [O’Brien et al 2017, Boland and Ahmedzai 2017].  
 
Access to oncological and surgical management options to control pain should be available 
regionally within each country. For example, radiotherapy for bone metastases, spinal stabilization, 
surgical fixation of pathological fractures, vertebroplasty or palliative debulking of tumor. 
 
Standard 5. Support and advice for self-management should be provided [GRADE 1A] 
 
Self-management is the capability of a patient to manage their pain, their analgesic treatments and 
the physical and psychological consequences of living with cancer-related pain [Johnston et al 2014]. 
This involves a number of skills and activities including getting the right information, managing 
practical tasks and emotions, solving problems and knowing what to do when symptoms get worse 
or more help is needed [Schumacher et al 2014]. Most patients want help to manage themselves, 
but their ability to do this is influenced by their emotional state and their physical health.  
 
Addressing concerns about pain and strong opioids, and providing strategies that help patients 
though provision of educational materials, improve patient outcomes and should be routine practice 
[Bennett et al 2009, Sheinfeld-Gorin et al 2012, Oldenmenger et al 2018]. This information must 
cover how to take analgesia, the likely effectiveness of this, how to monitor side effects, plans for 
further follow up, and how to get help especially out of hours. All members of the healthcare team 
have a role in supporting self-management including doctors, nurses pharmacists and others.  
  
Standard 6. The pain management plan should be reviewed regularly to assess outcomes and plan 
longer-term care [GRADE 1B] 
Although patients understandably express that they want to be pain free, in general, they do not 
actually expect their pain to go completely [Gibbins et al 2014]. Most patients seem to determine 
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relationships with family or friends. The outcome in terms of the balance of residual pain and 
functioning is individually determined. 
 
Patients should know who is responsible for reviewing their pain management plan, when this 
review is expected to take place and whether this can be done face-to-face, by telephone or digital 
technology [Adam et al 2017]. Contact information for out of hours support should be easily 
accessible. Telephone support from a nurse or pharmacist integrated with electronic symptom 
monitoring is an effective method of follow up for pain and analgesia [Kroenke et al 2010, 
Oldenmenger et al 2011]. 
 
Standard 7. Patients should be referred for more specialist advice and treatment if pain is not 
improving within a short time or if they are experiencing intolerable side-effects of analgesia 
[GRADE 1C] 
 
Patients should be referred for specialist support if pain is not well controlled despite initial 
management or the pain has been identified as complex. Specialist support must be available 
regionally within each country in the form of specialist multidisciplinary pain services, oncology 
services including radiotherapy and palliative care services. Access to specialist services for pain that 
is insufficiently responding to standard care should be readily available regionally within one week 
[IASP 2018]. This includes access to advanced pain management techniques such as intrathecal 
pumps and neuro-ablative techniques [Smith et al 2002, Vayne-Bossert et al 2016, Bruel and Burton 
2016]. Early referral to specialist services is needed when pain is complex or not responding to initial 
treatment, rather than waiting until all conventional approaches have been exhausted and the 
patient is too unwell for advanced pain management intervention.  
 
Patients who present with severe uncontrolled pain, significant drug related adverse events or 
extreme psychological distress should also be referred urgently to a specialized care facility [IASP 
2018]. Healthcare professionals should be aware of appropriate specialized care facilities with 
specific and targeted multidimensional expertise in the management of cancer pain nationally. 
Established referral pathways should exist between oncology, pain and palliative care services to co-
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With improved early cancer diagnosis and enhanced treatments, many patients are now living with 
cancer as a chronic disease. Increasing numbers of patients experience cure or prolonged remission 
and are regarded as cancer survivors. Some of these patients will continue to experience pain which 
negatively affects their quality of life [Glare et al 2014]. Some patients may continue to use high 
doses of opioid, previously required for adequate pain control, but which are no longer needed 
while causing side-effects. These patients require more specialist help which is likely to include long-
term self-management plans, medication weaning plans and pain rehabilitation and occupational 
therapy interventions [Paice et al 2016]. Such plans are typically offered by chronic pain 
management programs and pain clinicians with a special interest in opioid management. Each 
country should have national guidance on managing and referring patients with long-term pain from 
cancer treatments.  
 
Standard 8. Healthcare professionals who treat patients with cancer should receive ongoing 
education and training in order to undertake basic pain assessment, initiate basic management, 
and learn about correctly referring for more specialist support [GRADE 1C] 
 
Significant gaps in knowledge on cancer pain diagnosis and management by healthcare professionals 
are well documented in the medical literature, leading to inadequate relief in a substantial number 
of patients with cancer pain [Oldenmenger et al 2009]. Proper education and training is therefore 
essential. EFIC recommends its chapters to develop educational programs on cancer pain at 
undergraduate level (medical and nursing schools), postgraduate level for all health care professions 
who are involved in the care of patients with cancer, and finally within specialized programs within 
training in pain and palliative medicine. An example of the contents of such educational programs 
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Standard 9. Regular review of service outcomes for all patients with cancer pain should be in place 
[GRADE 1C] 
 
Regular review of outcomes for patients enables services to identify areas for improvement, 
focusing on safety and efficacy data of various methods of pain control. Novel methods for 
supporting patients to complete outcome measures are needed, for example using electronic or 
digital technology [Adam et al 2017]. 
 
 
Standard 10. Each EFIC chapter should have national evidence or consensus based guidelines in 
place for cancer-related pain [GRADE 1C] 
 
Many international and national guidelines on cancer pain assessment and treatment are available 
but they may not be suitable for all countries [Piano et al 2014]. EFIC recommends that its chapters 
should produce an appropriate treatment guideline for cancer-related pain that is valid for the 
circumstances according to each country's needs acknowledging variations in access to drugs and 
other treatments, and respecting social and cultural identity. Such guidelines can be adapted from 
existing international or national guidelines in other countries. Production of lay versions which can 
be understood by non-health care professionals should be considered.  
 
We recommend that each country will develop a mechanism, by either professional organizations or 
through regulatory authorities, to monitor and assess the implementation and usage of national 
guidelines and European standards.  
 
Summary 
The 10 standards presented are aimed to improve cancer pain management and reduce variation 
across Europe. We believe that adoption of these standards by all 37 countries will promote the 
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continuously support enhancing the quality of cancer pain management through its pain schools, 
special sessions in conferences and reviewing and when necessary revising this document in the 
future.    
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Table 1. Proposed ICD-11 classification of cancer-related pain  
 
Level 1 Level 2 Level 3 Level 4 
Cancer-related 
pain 
Cancer pain Visceral cancer pain  
  Bony cancer pain  
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Table 2. Structured pain assessment 
 
History  Pain location, onset, duration, severity, 
quality, alleviating and aggravating factors. 
Special emphasis on episodic pain 
 Impact on mood, usual activities, function, 
quality of life and sleep 
 Previous pain and treatment history 
 Ongoing response to treatment, adverse 
effects 
 Comorbidities impacting pain (e.g., chronic 
disease, surgery, trauma, mood, cognitions, 
substance use disorder, medications) 
 Personal characteristics (e.g., age, sex, race, 
religion, culture, language) 
 Expectations of pain management and 
current understanding of the condition, 
including what significance the patient 
attaches to the pain  
Physical examination  
(focused according to the 
presenting condition) 
Relevant, physical, neurological and 
musculoskeletal assessment 
Review of clinical records 
 
Co-morbid diseases, previous chronic pain 
history, age-related frailty 
Investigations  Laboratory tests 
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Table 3. Essential analgesic drugs  
 
Drug class Examples 
Simple analgesia Paracetamol 
Non-steroidal anti-inflammatory drugs (NSAIDs) including coxibs 
Opioids Opioids for moderate intensity pain:  
Codeine, dihydrocodeine, tramadol 
 
Opioids for moderate to severe intensity pain:  
Immediate release opioids as oral and injectable formulations 
(morphine, oxycodone, hydromorphone);  
 
Sustained release opioids as oral (morphine, oxycodone,  
tapentadol, hydromorphone;) and transdermal (fentanyl, 
buprenorphine) formulations,  
 
Opioids for specialist use only  
Rapid onset transmucosal fentanyl based formulations  
Methadone  
Antidepressants  Amitriptyline, imipramine, duloxetine, venlafaxine 
Anti-epileptics Gabapentin, pregabalin, carbamazepine 
Corticosteroids Prednisolone, dexamethasone 
Bisphosphonates Pamidronate, Zoledronate 
Monoclonal antibodies Denosumab, Tanezumab 
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1A. Strong recommendation, high quality evidence 
1B. Strong recommendation, moderate quality evidence 
1C. Strong recommendation, low quality evidence 
2A. Weak recommendation, high quality evidence 
2B. Weak recommendation, moderate quality evidence 
2C. Weak recommendation, low quality evidence 
 
 
